• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

[一剂亚胺培南/西司他丁后骨中亚胺培南的浓度]

[Bone concentrations of imipenem after a dose of imipenem/cilastatin].

作者信息

Wittmann D H, Kuipers T H, Fock R, Höll M, Bauernfeind A

出版信息

Infection. 1986;14 Suppl 2:S130-7. doi: 10.1007/BF01647497.

DOI:10.1007/BF01647497
PMID:3463540
Abstract

The concentration of imipenem in organic bone, determined in 16 patients by bioassay after short infusion (15 min) of 1 g imipenem/cilastatin was 4.3 +/- 2.06 mg/kg (geometric mean +/- standard deviation, n = 13) after 45 minutes, and 2.8 +/- 1.86 mg/kg (n = 26) after 88 minutes. Imipenem penetrates into inorganic hydroxylapatite (imbution), however, its antimicrobial activity is lost. The mean serum concentration in 12 patients (mean age 77 years) with normal renal and hepatic function 15 minutes after the beginning of the infusion was 93.1 mg/l imipenem. The mean serum half life t (1/2 beta) was 1.32 hours, the total body clearance 108.6 1/h, and the volume of distribution during the beta phase V(beta) 12.4 1.

摘要

在16例患者中,静脉快速输注(15分钟)1克亚胺培南/西司他丁后,通过生物测定法测定的有机骨中亚胺培南浓度在45分钟时为4.3±2.06毫克/千克(几何平均数±标准差,n = 13),88分钟时为2.8±1.86毫克/千克(n = 26)。亚胺培南可渗入无机羟基磷灰石(吸附),但其抗菌活性丧失。12例肾功能和肝功能正常的患者(平均年龄77岁)在输注开始15分钟后的平均血清浓度为亚胺培南93.1毫克/升。平均血清半衰期t(1/2β)为1.32小时,全身清除率为108.6升/小时,β相分布容积V(β)为12.4升。

相似文献

1
[Bone concentrations of imipenem after a dose of imipenem/cilastatin].[一剂亚胺培南/西司他丁后骨中亚胺培南的浓度]
Infection. 1986;14 Suppl 2:S130-7. doi: 10.1007/BF01647497.
2
[Imipenem/cilastatin: in vitro activity, concentrations in plasma and prostatic adenoma and therapeutic results in patients with complicated urinary tract infections].亚胺培南/西司他丁:体外活性、血浆和前列腺腺瘤中的浓度以及复杂性尿路感染患者的治疗结果
Infection. 1986;14 Suppl 2:S122-9. doi: 10.1007/BF01647496.
3
Pharmacokinetic studies of imipenem/cilastatin in elderly patients.亚胺培南/西司他丁在老年患者中的药代动力学研究。
J Antimicrob Chemother. 1986 Dec;18 Suppl E:103-7. doi: 10.1093/jac/18.supplement_e.103.
4
Multiple-dose pharmacokinetics of imipenem-cilastatin.亚胺培南-西司他丁的多剂量药代动力学。
Antimicrob Agents Chemother. 1984 Nov;26(5):715-21. doi: 10.1128/AAC.26.5.715.
5
The pharmacokinetics of imipenem (thienamycin-formamidine) and the renal dehydropeptidase inhibitor cilastatin sodium in normal subjects and patients with renal failure.亚胺培南(硫霉素-甲脒)和肾脏脱氢肽酶抑制剂西司他丁钠在正常受试者和肾衰竭患者中的药代动力学。
Br J Clin Pharmacol. 1984 Aug;18(2):183-93. doi: 10.1111/j.1365-2125.1984.tb02451.x.
6
The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers.在六名正常志愿者中,高剂量(1克)亚胺培南与1克西司他丁联合使用时的血浆药代动力学。
Eur J Clin Microbiol. 1984 Oct;3(5):468-70. doi: 10.1007/BF02017377.
7
Imipenem/cilastatin: pharmacokinetic profile in renal insufficiency.
Am J Med. 1985 Jun 7;78(6A):54-61. doi: 10.1016/0002-9343(85)90102-0.
8
Pharmacokinetic profile of imipenem/cilastatin in normal volunteers.
Am J Med. 1985 Jun 7;78(6A):47-53. doi: 10.1016/0002-9343(85)90101-9.
9
Single-dose pharmacokinetics of imipenem-cilastatin in pediatric patients.
Pediatr Pharmacol (New York). 1986;5(4):273-9.
10
Single-dose pharmacokinetics of imipenem-cilastatin in neonates.亚胺培南-西司他丁在新生儿中的单剂量药代动力学。
Antimicrob Agents Chemother. 1985 Apr;27(4):511-4. doi: 10.1128/AAC.27.4.511.

引用本文的文献

1
Functionalization of Synthetic Bone Substitutes.合成骨替代物的功能化。
Int J Mol Sci. 2021 Apr 23;22(9):4412. doi: 10.3390/ijms22094412.
2
Systemic antibiotic therapy for chronic osteomyelitis in adults.成人慢性骨髓炎的全身抗生素治疗。
Clin Infect Dis. 2012 Feb 1;54(3):393-407. doi: 10.1093/cid/cir842. Epub 2011 Dec 12.
3
Penetration of antibacterials into bone: pharmacokinetic, pharmacodynamic and bioanalytical considerations.抗菌药物在骨组织中的渗透:药代动力学、药效学及生物分析学考量

本文引用的文献

1
In vitro activity of N-formimidoyl thienamycin (MK0787).N-甲酰亚胺基硫霉素(MK0787)的体外活性
Antimicrob Agents Chemother. 1980 Oct;18(4):642-4. doi: 10.1128/AAC.18.4.642.
2
MK0787 (N-formimidoyl thienamycin): evaluation of in vitro and in vivo activities.MK0787(N-亚胺甲酰硫霉素):体内外活性评估
Antimicrob Agents Chemother. 1980 Jun;17(6):993-1000. doi: 10.1128/AAC.17.6.993.
3
N-formimidoyl-thienamycin a novel beta-lactam: an in-vitro comparison with other beta-lactam antibiotics.N-甲脒基硫霉素一种新型β-内酰胺:与其他β-内酰胺抗生素的体外比较。
Clin Pharmacokinet. 2009;48(2):89-124. doi: 10.2165/00003088-200948020-00002.
4
Clinical pharmacokinetics of enzyme inhibitors in antimicrobial chemotherapy.抗菌化疗中酶抑制剂的临床药代动力学
Clin Pharmacokinet. 1988 Sep;15(3):133-64. doi: 10.2165/00003088-198815030-00001.
J Antimicrob Chemother. 1981 May;7(5):521-9. doi: 10.1093/jac/7.5.521.
4
The plasma pharmacokinetics of high dose (1 g) imipenem coadministered with 1 g cilastatin in six normal volunteers.在六名正常志愿者中,高剂量(1克)亚胺培南与1克西司他丁联合使用时的血浆药代动力学。
Eur J Clin Microbiol. 1984 Oct;3(5):468-70. doi: 10.1007/BF02017377.
5
Pharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humans.N-甲酰亚胺基硫霉素(MK0787)在人体中的药代动力学和耐受性。
Antimicrob Agents Chemother. 1983 Feb;23(2):293-9. doi: 10.1128/AAC.23.2.293.
6
In vitro activity of imipenem--a review.亚胺培南的体外活性——综述
Eur J Clin Microbiol. 1984 Oct;3(5):456-62. doi: 10.1007/BF02017375.
7
[Use of hydroxyapatite for determination of antibiotic concentrations in bone].[使用羟基磷灰石测定骨中抗生素浓度]
Arzneimittelforschung. 1983;33(3):423-6.
8
Antibacterial activity of N-formimidoyl thienamycin in comparison with cefotaxime, lamoxactam, cefoperazone, piperacillin gentamicin.与头孢噻肟、拉氧头孢、头孢哌酮、哌拉西林-庆大霉素相比,N-甲脒硫霉素的抗菌活性。
Infection. 1982 Jan;10(1):45-9. doi: 10.1007/BF01640838.
9
Simplified, accurate method for antibiotic assay of clinical specimens.临床标本抗生素检测的简化、准确方法。
Appl Microbiol. 1966 Mar;14(2):170-7. doi: 10.1128/am.14.2.170-177.1966.
10
[Pharmacokinetics of propicillin in geriatric patients in comparison with younger adults].老年患者与年轻成年人相比的丙匹西林药代动力学
Dtsch Med Wochenschr. 1972 Dec 29;97(52):1999-2003. doi: 10.1055/s-0028-1107695.